Is Exomind Safe?

Key Takeaways

EXOMIND is a medical device that delivers repetitive transcranial magnetic stimulation, or rTMS. BTL describes EXOMIND as using its ExoTMS technology. The broad safety principles therefore come from the established rTMS field, but the exact device labeling, protocol and intended use still matter.[1][3][4]

In practical terms, safe treatment means more than asking whether TMS is generally safe. It means checking whether the indication, device, stimulation protocol and patient circumstances fit together. A person may have no obvious medical problem and still not be an appropriate candidate for a particular indication or protocol.

Suitability is indication-specific. The Malaysian Medical Device Authority currently lists EXOMIND as an rTMS system. Its registered intended purposes include treatment of major depressive disorder in adults who have not achieved satisfactory improvement from prior antidepressant medication at or above the minimal effective dose and duration in the current episode, reduction of comorbid anxiety symptoms in adults with MDD, adjunctive treatment of adult OCD, and treatment of binge-eating disorder.[2]

A clinician may therefore consider a patient when the condition being treated matches the relevant indication, the expected benefit is meaningful, the person can complete screening and treatment safely, and the medical history, implants, medicines and other risk factors are compatible with the device and protocol.[2][3][4]

Some circumstances can make rTMS unsuitable, while others require a more detailed risk-benefit review. The presence of one risk factor does not automatically mean treatment is permanently impossible, because the answer can depend on the exact device, implant, protocol and clinical situation.[3][4]

Patients should not use a generic internet checklist to self-clear themselves. Current expert guidance recommends device-specific assessment when compatibility is uncertain.[3][4]

A good screening appointment is designed to identify safety issues before the first stimulation session. The clinician will usually review the reason for treatment, relevant medical and psychiatric history, previous treatment, medicines and substances, neurological risk factors, implanted devices and other factors that could affect the procedure.[3][4][6]

The screening discussion should also cover what the session will feel and sound like, hearing protection, how side effects are reported, and what happens if the patient becomes unwell. TMS is delivered while the patient is awake, and services should have procedures for uncommon but important events such as seizure or fainting.[3][4]

Most people receiving rTMS remain awake and can communicate during treatment. Common sensations are local: tapping or knocking on the scalp, tingling, muscle twitching near the face or scalp, temporary scalp discomfort and headache. Dizziness or lightheadedness can also occur. NIMH describes rTMS as generally safe and well tolerated, while noting that side effects are possible and that long-term safety continues to be studied.[5]

Seizure is a recognized but rare complication. Clinicians also monitor for clinically significant worsening of mood or other psychiatric symptoms in patients being treated for serious mental illness. This monitoring reflects the need to watch the underlying illness and treatment response, not a claim that rTMS routinely causes suicidality.[3][4]

Implants and Metal

This is one of the most important safety questions before EXOMIND. Certain conductive, ferromagnetic or magnetically sensitive materials can interact with the magnetic field, and electronic implants may malfunction or be affected. FDA guidance therefore calls for careful screening of implanted and nearby devices, with particular attention to metal or active implants in or near the treatment area.[3]

Do not self-clear an implant because it is described as titanium, MRI-compatible, small or far from the brain. The exact device and its compatibility requirements should be checked against the current EXOMIND/device labeling and, where necessary, the implant manufacturer's information.[3][4]

Medicines and Substances

Medication review does not mean that patients should stop their medicines before TMS. Some medicines and substances can affect seizure threshold, while abrupt medication changes can themselves create clinical problems. Expert guidance supports documenting concurrent medicines and considering recent changes as part of the overall risk assessment.[4][7]

• Give the clinic a complete list of prescribed medicines, over-the-counter medicines and supplements.
• Tell the clinician about recent medication starts, stops or dose changes.
• Do not suddenly stop antidepressants, benzodiazepines, anticonvulsants or other medicines unless the prescribing clinician directs you to.
• Tell the team about heavy alcohol use, recreational substances or recent withdrawal.

EXOMIND is non-invasive, meaning there is no surgery or needle placed into the brain. BTL describes EXOMIND sessions as lasting under 30 minutes and states that treatment is performed under physician or licensed-practitioner supervision with patient monitoring.[1]

Before the session, the team should confirm that there have been no important changes in health, medicines or other safety factors. During stimulation, a patient may hear clicking and feel tapping, tingling or brief muscle contractions. Hearing protection is an established safety precaution for rTMS.[3][5]

After the session, patients can report headache, discomfort, dizziness or other symptoms. Because EXOMIND does not require general anaesthesia, there is no anaesthetic recovery period. The exact number and timing of sessions depend on the indication and protocol. A shorter treatment course should not automatically be interpreted as safer or more effective.[1][9][10][11]

The broader rTMS safety evidence is much larger than the EXOMIND-specific evidence. NIMH describes rTMS as generally safe and well tolerated, and expert guidelines report that seizure risk is low with traditional stimulation parameters and appropriate safety procedures.[4][5]

EXOMIND-specific studies and reviews add useful device-specific information, but they are newer and smaller. A 2025 ExoTMS study in patients with binge-eating symptoms and a 2026 review of ExoTMS clinical evidence provide evidence about particular populations and protocols. They do not establish that every EXOMIND protocol has the same safety profile as the broader rTMS literature, nor do they establish long-term safety for every patient.[9][10]

In Malaysia, the Medical Device Authority register lists EXOMIND, registration number GB6594125-201327, with registration validity from 15 April 2025 to 14 April 2030. The register specifies the device as an rTMS system and states its intended purposes. Registration is a regulatory status within a defined framework, not a statement that the treatment is superior to alternatives or appropriate for everyone.[2]

Most TMS side effects are mild and short-lived, but patients should tell the treating team if symptoms are unusually severe, persistent or different from what was explained before treatment. Significant changes in medical status or medication during a treatment course should also be reported.[3][4][5]

• Severe or persistent headache or treatment-site pain that does not settle as expected.
• Repeated or significant dizziness, fainting or other symptoms that interfere with normal activity.
• New neurological symptoms or a reaction that feels substantially different from previous sessions.
• A significant change in mood, agitation, behaviour or suicidal thinking.
• A new medication, major medication dose change or abrupt medication withdrawal.
• A newly discovered implanted device, metal fragment or other information that was not disclosed during screening.

The useful question is not simply 'Is EXOMIND safe?' It is 'Is EXOMIND appropriate and acceptably safe for me, given my condition, medical history, implants, medicines and current health?'

Current evidence supports the general safety of rTMS when appropriate protocols, screening and clinical procedures are used. The common problems are usually temporary scalp discomfort, headache, tingling or muscle twitching, and dizziness. Seizure remains the most important serious acute risk, but it is rare. EXOMIND-specific evidence is growing, but it remains smaller and newer than the broader TMS evidence base.[3][4][5][9][10]